---
title: 'Pfizer, Cerevel, Abbott, AstaZeneca + Daiichi Sankyo'
type: 'episode'
url: 'https://doc.social/episodes/pfizer-cerevel-abbott-astazeneca-daiichi-sankyo'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-08-17'
audio: 'unavailable — the host retired the file'
---

# Pfizer, Cerevel, Abbott, AstaZeneca + Daiichi Sankyo

Spending that COVID money, brain money, Irish money, and another oncology approval. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesPfizerCerevelAbbottAstaZeneca + Daiichi SankyoAbout the ShowLife Science Today is your so…

## Summary

Spending that COVID money, brain money, Irish money, and another oncology approval.

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References
**[Pfizer](https://www.yahoo.com/video/pfizer-scoops-sickle-disease-player-120738531.html)**
**[Cerevel](https://www.biospace.com/article/releases/cerevel-therapeutics-announces-pricing-of-300-million-private-offering-of-convertible-senior-notes-and-concurrent-254-million-public-offering-of-common-stock/?s=80)**
**[Abbott](https://enterprise.gov.ie/en/news-and-events/department-news/2022/august/12082022.html)**
**[AstaZeneca + Daiichi Sankyo
](https://www.biospace.com/article/releases/enhertu-fam-trastuzumab-deruxtecan-nxki-approved-in-the-us-as-the-first-her2-directed-therapy-for-patients-with-previously-treated-her2-mutant-metastatic-non-small-cell-lung-cancer/?s=74)
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.